Vidaza and condition aggravated Patient Reports February 11, 2012

Vidaza Side Effects Report #5804010-9
Vidaza side effect was reported by a Physician from UNITED STATES on June 19, 2008. Male patient, 81 years of age, weighting 167.6 lb, was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: cardio-respiratory arrest, condition aggravated, hypoxia, lobar pneumonia, neutropenia. Vidaza dosage: (75 MG/M2,DAILY X 5 DAYS), SUBCUTANEOUS. During the same period patient was treated with COMPAZINE, LISINOPRIL, NIFEDIPINE, METOPROLOL SUCCINATE, FUROSEMIDE, SYNTHROID, ASPIRIN, CORGARD. Patient was hospitalized. Patient died on 04/12/2008.

Vidaza Side Effects Report #4867941-2
Vidaza side effect was reported by a Physician from SWITZERLAND on Dec 16, 2005. Male patient, 81 years of age, weighting 172.0 lb, was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: aortic arteriosclerosis, atrial fibrillation , cerebrovascular accident, condition aggravated, confusional state, embolism, fall , performance status decreased, renal impairment. Vidaza dosage: 120 MG (120 MG, ONCE DAILY X 7 DAYS), SUBCUTANEOUS. During the same period patient was treated with ATENOLOL, TORASEMIDE, FOLIC ACID. Patient was hospitalized. Patient recovered.

Vidaza Side Effects Report #5777991-X
Vidaza side effect was reported by a Physician from UNITED STATES on June 04, 2008. Female patient, 72 years of age, weighting 123.5 lb, was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: bronchopulmonary aspergillosis, condition aggravated, pancytopenia. Vidaza dosage: 120 MG/M2, DAILY X 7 DAYS, INTRAVENOUS. During the same period patient was treated with LISINOPRIL, FUROSEMIDE, CYCLOSPORINE, CARVEDILOL, PREDNISONE. Patient was hospitalized. Patient recovered.

Vidaza Side Effects Report #6044426-1
Vidaza side effect was reported by a Health Professional from UNITED STATES on Jan 15, 2009. Male patient, 71 years of age, weighting 191.0 lb, was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: atelectasis, atrial fibrillation , blood magnesium decreased, cardiac failure congestive, cardiomegaly, condition aggravated, dyspnoea, ejection fraction decreased, fatigue. Vidaza dosage: 108MG EVERY OTHER DAY, X2WEEKS Q4WEEKS : SUBCUTANEOUS. Patient was hospitalized. Patient recovered.


Vidaza Side Effects Report #5195824-X
Vidaza side effect was reported by a Physician from UNITED STATES on Dec 14, 2006. Female patient, 69 years of age, weighting 158.0 lb, was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: asthenia, bacteria stool identified, bacterial infection , blood pressure decreased, catheter sepsis, condition aggravated, heart rate decreased, heart rate increased, nausea . Vidaza dosage: 75 MG/M2 (DAILY X 5 DAYS), INTRAVENOUS. During the same period patient was treated with ZOLOFT, XANAX, ASCORBIC ACID, IRON, CYANOCOBALAMIN, SPIRIVA, ALBUTEROL. Patient was hospitalized. Patient died on 12/12/2006.

Vidaza Side Effects Report #5191605-1
Vidaza side effect was reported by a Physician from ITALY on Dec 04, 2006. Female patient, 66 years of age, weighting 130.1 lb, was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: cerebral ischaemia, coagulopathy, coma hepatic, condition aggravated, hepatic failure, hepatic necrosis, hepatotoxicity, international normalised ratio increased, neutrophil count decreased. Vidaza dosage: 60 MG/M2 (100 MG, DAILY X 8 DAYS, WITHOUT WEEKEND DOSING), SUBCUTANEOUS. During the same period patient was treated with VALPROIC ACID, DANAZOLE, TRETINOIN. Patient died on 10/24/2006.

Vidaza Side Effects Report #5189382-3
Vidaza side effect was reported by a Health Professional from FRANCE on Dec 01, 2006. Male patient, 65 years of age, was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: bone marrow failure, bone marrow transplant , bronchopulmonary aspergillosis, condition aggravated, febrile bone marrow aplasia, pancytopenia. Vidaza dosage: 75 MG/M2 (DAILY X 6 DAYS), SUBCUTANEOUS. During the same period patient was treated with DANATROL, ARANESP. Patient was hospitalized. Patient recovered.

Vidaza Side Effects Report #4773089-8
Vidaza side effect was reported by a Physician from UNITED STATES on Sept 01, 2005. Male patient, 64 years of age, weighting 157.0 lb, was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: cardiac failure congestive, condition aggravated, platelet count decreased, pneumonia , white blood cell count decreased. Vidaza dosage: unknown. During the same period patient was treated with PROCRIT, CARDIZEM, LASIX. Patient was hospitalized. Patient died on 07/31/2005.

Vidaza Side Effects Report #4638334-8
Vidaza side effect was reported by a Physician from on Apr 04, 2005. Female patient was diagnosed with myelodysplastic syndrome and was treated with Vidaza. After drug was administered, patient experienced the following side effects: acute pulmonary oedema, cardiac failure, cerebrovascular accident, condition aggravated, haemoglobin decreased, neutropenia, platelet count decreased, platelet count increased, pneumonia . Vidaza dosage: 150 MG ( 7 DAYS/MONTH), SUBCUTANEOUS. During the same period patient was treated with OFLOCET, AMPICILLIN. Patient was hospitalized. Patient died on 04/01/2005.


Vidaza Side Effects Report #5343436-7
Vidaza side effect was reported by a Physician from UNITED KINGDOM on May 17, 2007. Male patient, 55 years of age, weighting 188.7 lb, was diagnosed with acute myeloid leukaemia and was treated with Vidaza. After drug was administered, patient experienced the following side effects: blood culture positive, blood pressure systolic decreased, condition aggravated, neutropenic sepsis, pseudomonas infection, refusal of treatment by patient, sputum culture positive, white blood cell count decreased. Vidaza dosage: 75 MG/M2 (150 MG ONCE DAILY X FIVE DAYS), SUBCUTANEOUS. During the same period patient was treated with VALPROATE, THEOPHYLLINE, ATRA, VALACYCLOVIR, METRONIDAZOLE, ADCORTYL IN ORAL BASE, AMILORIDE. Patient was hospitalized. Patient died on 05/09/2007.